for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pfizer Inc.

PFE.N

Latest Trade

38.22USD

Change

-0.26(-0.68%)

Volume

3,615,153

Today's Range

38.20

 - 

38.57

52 Week Range

33.97

 - 

44.89

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
38.48
Open
38.36
Volume
3,615,153
3M AVG Volume
399.77
Today's High
38.57
Today's Low
38.20
52 Week High
44.89
52 Week Low
33.97
Shares Out (MIL)
5,534.12
Market Cap (MIL)
212,953.00
Forward P/E
13.03
Dividend (Yield %)
3.74

Next Event

Q4 2019 Pfizer Inc Earnings Release

Latest Developments

More

ContraFect Prices About $10 Mln Public Offering Of Common Stock And Concurrent $3 Mln Private Placement Of Common Stock To Pfizer

Trevena Says Co, Pfizer Entered Into Amendment To Development & Supply Agreement, Dated Dec. 15, 2016

Pfizer Says FDA Approved Its Biosimilar, Abrilada For Multiple Inflammatory Conditions

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pfizer Inc.

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Industry

Biotechnology & Drugs

Contact Info

235 E 42ND ST

+1.212.5732323

https://www.pfizer.com/

Executive Leadership

Ian C. Read

Executive Chairman of the Board

Albert Bourla

Chief Executive Officer, Director

Frank A. D'Amelio

Chief Financial Officer, Executive Vice President - Business Operations

Mikael G. Dolsten

President - Worldwide Research and Development

Michael Goettler

Group President - Pfizer Upjohn

Key Stats

2.54 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

52.8K

2017

52.5K

2018

53.6K

2019(E)

51.8K
EPS (USD)

2016

2.400

2017

2.650

2018

3.000

2019(E)

2.954
Price To Earnings (TTM)
14.16
Price To Sales (TTM)
4.02
Price To Book (MRQ)
3.27
Price To Cash Flow (TTM)
9.81
Total Debt To Equity (MRQ)
80.89
LT Debt To Equity (MRQ)
55.36
Return on Investment (TTM)
11.37
Return on Equity (TTM)
9.13

Latest News

Latest News

Pfizer, Novartis lead $2 billion spending spree on gene therapy production

Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control production of the world's priciest medicines.

FOCUS-Pfizer, Novartis lead pharma spending spree on gene therapy production

Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control production of the world's priciest medicines.

European agency highlights blood clot risks from Pfizer's arthritis drug

Pfizer Inc's rheumatoid arthritis drug Xeljanz could increase the risk of blood clots in the lungs and in deep veins, the European Medicines Agency (EMA) said on Thursday.

Pfizer raises 2019 forecast as sales of cancer drug, heart medicine surge

Pfizer Inc <PFE.N> reported a higher-than-expected third-quarter profit on Tuesday on increased sales of cancer drug Ibrance and a strong launch of new heart medicine Vyndaqel, prompting the largest U.S. drugmaker to lift its earnings forecast for the year.

US STOCKS SNAPSHOT-Merck, Pfizer spur S&P 500 to record high; Alphabet weighs on Nasdaq

The S&P 500 hit a fresh record high on Tuesday, lifted by upbeat earnings from drugmakers Merck and Pfizer, while disappointing quarterly profit from Google-parent Alphabet kept the Nasdaq firmly in the negative territory.

US STOCKS SNAPSHOT-Wall Street dips at open after mixed earnings reports

Wall Street opened slightly lower on Tuesday as investors assessed a mixed batch of earnings reports, including from Google-parent Alphabet and big drugmakers Merck and Pfizer.

Pfizer raises 2019 profit forecast, shares rise

U.S. drugmaker Pfizer Inc raised its 2019 full-year earnings forecast on Tuesday, sending its shares up 3%.

Fitbit in healthcare partnership to take on Apple Watch

Fitbit Inc <FIT.N> is developing a method to detect irregular heart rhythm in time through a partnership with Bristol-Myers Squibb-Pfizer Alliance, as the wearable device maker looks to match a feature available on rival Apple Inc's <AAPL.O> Watch.

Novartis says Kisqali boosts survival in breast cancer patients

Novartis said on Sunday that Kisqali helped women with advanced breast cancer after menopause live longer, adding to data the Swiss company hopes will help convince doctors to choose its drug over Pfizer's blockbuster Ibrance.

Pfizer veteran Ian Read to retire as executive chairman

Pfizer Inc <PFE.N> said on Friday Ian Read will retire as executive chairman at the end of this year, after a four-decade association with the largest U.S. drugmaker that included eight years as chief executive officer.

Ian Read to retire as Pfizer executive chairman

Pfizer Inc said on Friday Ian Read will retire as executive chairman at the end of this year, ending a four-decade association with the largest U.S. drugmaker.

Ted Baker taps Debenhams executive Osborne as new CFO

British fashion retailer Ted Baker Plc <TED.L> said on Thursday Rachel Osborne will become its new finance chief once she steps down from the same position at Debenhams, following just one year in the role at the department store chain.

Novartis wins FDA's breakthrough tag for lung cancer hopeful

Novartis has secured the U.S. Food and Drug Administration's Breakthrough Therapy Designation for its investigational medicine capmatinib, which it aims to file for approval later this year against a mutated form of lung cancer.

UPDATE 1-Novartis joins Pfizer with FDA fast-track tag for lung cancer hopeful

Novartis has nabbed the U.S. Food and Drug Administration's breakthrough therapy designation for its experimental medicine capmatinib as it joins Pfizer in the race to treat a tough-to-treat mutated lung cancer type.

Pfizer invests $500 million in expanding gene therapy facility

Pfizer Inc is investing $500 million to expand a manufacturing facility in Sanford, North Carolina, that plays a central role in its efforts to become a major player in gene therapy, the company said on Wednesday.

J&J says FTC probing efforts to protect arthritis drug Remicade

The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on...

Mylan deal puts future of its beleaguered EpiPen in spotlight

Mylan NV's <MYL.O> planned merger with Pfizer Inc's <PFE.N> off-patent branded drugs business may have boosted its share price on Monday, but one of its most pressing problems remains: shortages of its flagship EpiPen emergency allergy treatment.

Mylan deal puts future of its beleaguered EpiPen in spotlight

Mylan NV's <MYL.O> planned merger with Pfizer Inc's <PFE.N> off-patent branded drugs business may have boosted its share price on Monday, but one of its most pressing problems remains: shortages of its flagship EpiPen emergency allergy treatment.

Pfizer to spinoff, merge off-patent drugs unit with Mylan

Pfizer Inc <PFE.N> has agreed to spin off its off-patent branded drugs business and combine it with generic drugmaker Mylan NV <MYL.O>, a move that leaves Pfizer with its more profitable innovative drugs, including cancer treatment Ibrance and pneumonia vaccine Prevnar.

Deals of the day-Mergers and acquisitions

The following bids, mergers, acquisitions and disposals were reported by 2025 GMT on Monday:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up